Telix Pharmaceuticals is trading 7.17% down in pre-market at $11.53 after announcing an at-the-market facility allowing issuance of new ADSs, raising potential dilution concerns.
- August 20, 2026 half-year results were strong: revenue rose 22% to US$477 million, while adjusted EBITDA increased 146% to US$52 million.
- Management maintained fiscal-year revenue guidance; the facility’s capacity remains undisclosed, with pending regulatory catalysts.